Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

Peripheral Immune Biomarkers and Neurodegenerative Diseases: A Prospective Cohort Study with 20 Years of Follow-up.

Yazdani S, Mariosa D, Hammar N, Andersson J, Ingre C, Walldius G, Fang F.

Ann Neurol. 2019 Oct 11. doi: 10.1002/ana.25614. [Epub ahead of print]

PMID:
31604369
2.

Antibiotics use and risk of amyotrophic lateral sclerosis in Sweden.

Sun J, Zhan Y, Mariosa D, Larsson H, Almqvist C, Ingre C, Zagai U, Pawitan Y, Fang F.

Eur J Neurol. 2019 Nov;26(11):1355-1361. doi: 10.1111/ene.13986. Epub 2019 Jun 7.

PMID:
31087715
3.

Complications and outcome of percutaneous endoscopic gastrostomy in a high-volume centre.

Vujasinovic M, Ingre C, Baldaque Silva F, Frederiksen F, Yu J, Elbe P.

Scand J Gastroenterol. 2019 Apr;54(4):513-518. doi: 10.1080/00365521.2019.1594354. Epub 2019 Mar 24.

PMID:
30905223
4.

The Swedish motor neuron disease quality registry.

Longinetti E, Regodón Wallin A, Samuelsson K, Press R, Zachau A, Ronnevi LO, Kierkegaard M, Andersen PM, Hillert J, Fang F, Ingre C.

Amyotroph Lateral Scler Frontotemporal Degener. 2018 Nov;19(7-8):528-537. doi: 10.1080/21678421.2018.1497065. Epub 2018 Oct 9.

PMID:
30296856
5.

July 2017 ENCALS statement on edaravone.

Al-Chalabi A, Andersen PM, Chandran S, Chio A, Corcia P, Couratier P, Danielsson O, de Carvalho M, Desnuelle C, Grehl T, Grosskreutz J, Holmøy T, Ingre C, Karlsborg M, Kleveland G, Koch JC, Koritnik B, KuzmaKozakiewicz M, Laaksovirta H, Ludolph A, McDermott C, Meyer T, Mitre Ropero B, Mora Pardina J, Nygren I, Petri S, Povedano Panades M, Salachas F, Shaw P, Silani V, Staaf G, Svenstrup K, Talbot K, Tysnes OB, Van Damme P, van der Kooi A, Weber M, Weydt P, Wolf J, Hardiman O, van den Berg LH.

Amyotroph Lateral Scler Frontotemporal Degener. 2017 Nov;18(7-8):471-474. doi: 10.1080/21678421.2017.1369125. Epub 2017 Oct 4. Review. No abstract available.

6.

Neurodegenerative and psychiatric diseases among families with amyotrophic lateral sclerosis.

Longinetti E, Mariosa D, Larsson H, Ye W, Ingre C, Almqvist C, Lichtenstein P, Piehl F, Fang F.

Neurology. 2017 Aug 8;89(6):578-585. doi: 10.1212/WNL.0000000000004179. Epub 2017 Jul 12.

7.

Blood biomarkers of carbohydrate, lipid, and apolipoprotein metabolisms and risk of amyotrophic lateral sclerosis: A more than 20-year follow-up of the Swedish AMORIS cohort.

Mariosa D, Hammar N, Malmström H, Ingre C, Jungner I, Ye W, Fang F, Walldius G.

Ann Neurol. 2017 May;81(5):718-728. doi: 10.1002/ana.24936.

PMID:
28437840
8.

Predictors of health-related quality of life in people with amyotrophic lateral sclerosis.

Sandstedt P, Johansson S, Ytterberg C, Ingre C, Holmqvist LW, Kierkegaard M.

J Neurol Sci. 2016 Nov 15;370:269-273. doi: 10.1016/j.jns.2016.09.034. Epub 2016 Sep 21.

PMID:
27772773
9.

Depression in amyotrophic lateral sclerosis.

Roos E, Mariosa D, Ingre C, Lundholm C, Wirdefeldt K, Roos PM, Fang F.

Neurology. 2016 Jun 14;86(24):2271-7. doi: 10.1212/WNL.0000000000002671. Epub 2016 Apr 22.

10.

A 50 bp deletion in the SOD1 promoter lowers enzyme expression but is not associated with ALS in Sweden.

Ingre C, Wuolikainen A, Marklund SL, Birve A, Press R, Andersen PM.

Amyotroph Lateral Scler Frontotemporal Degener. 2016 Jul-Aug;17(5-6):452-7. doi: 10.3109/21678421.2016.1159223. Epub 2016 Mar 22.

PMID:
27002425
11.

Amyotrophic lateral sclerosis among cross-country skiers in Sweden.

Fang F, Hållmarker U, James S, Ingre C, Michaëlsson K, Ahlbom A, Feychting M.

Eur J Epidemiol. 2016 Mar;31(3):247-53. doi: 10.1007/s10654-015-0077-7. Epub 2015 Jul 29.

PMID:
26220522
12.

Risk factors for amyotrophic lateral sclerosis.

Ingre C, Roos PM, Piehl F, Kamel F, Fang F.

Clin Epidemiol. 2015 Feb 12;7:181-93. doi: 10.2147/CLEP.S37505. eCollection 2015. Review.

13.

No association between VAPB mutations and familial or sporadic ALS in Sweden, Portugal and Iceland.

Ingre C, Pinto S, Birve A, Press R, Danielsson O, de Carvalho M, Guđmundsson G, Andersen PM.

Amyotroph Lateral Scler Frontotemporal Degener. 2013 Dec;14(7-8):620-7. doi: 10.3109/21678421.2013.822515. Epub 2013 Aug 23.

PMID:
23971766
14.

A novel phosphorylation site mutation in profilin 1 revealed in a large screen of US, Nordic, and German amyotrophic lateral sclerosis/frontotemporal dementia cohorts.

Ingre C, Landers JE, Rizik N, Volk AE, Akimoto C, Birve A, Hübers A, Keagle PJ, Piotrowska K, Press R, Andersen PM, Ludolph AC, Weishaupt JH.

Neurobiol Aging. 2013 Jun;34(6):1708.e1-6. doi: 10.1016/j.neurobiolaging.2012.10.009. Epub 2012 Nov 8.

15.

Homozygous SMN2 deletion is a protective factor in the Swedish ALS population.

Corcia P, Ingre C, Blasco H, Press R, Praline J, Antar C, Veyrat-Durebex C, Guettard YO, Camu W, Andersen PM, Vourc'h P, Andres CR.

Eur J Hum Genet. 2012 May;20(5):588-91. doi: 10.1038/ejhg.2011.255. Epub 2012 Jan 25.

16.

A yeast functional screen predicts new candidate ALS disease genes.

Couthouis J, Hart MP, Shorter J, DeJesus-Hernandez M, Erion R, Oristano R, Liu AX, Ramos D, Jethava N, Hosangadi D, Epstein J, Chiang A, Diaz Z, Nakaya T, Ibrahim F, Kim HJ, Solski JA, Williams KL, Mojsilovic-Petrovic J, Ingre C, Boylan K, Graff-Radford NR, Dickson DW, Clay-Falcone D, Elman L, McCluskey L, Greene R, Kalb RG, Lee VM, Trojanowski JQ, Ludolph A, Robberecht W, Andersen PM, Nicholson GA, Blair IP, King OD, Bonini NM, Van Deerlin V, Rademakers R, Mourelatos Z, Gitler AD.

Proc Natl Acad Sci U S A. 2011 Dec 27;108(52):20881-90. doi: 10.1073/pnas.1109434108. Epub 2011 Nov 7.

17.

Ataxin-2 intermediate-length polyglutamine expansions in European ALS patients.

Lee T, Li YR, Ingre C, Weber M, Grehl T, Gredal O, de Carvalho M, Meyer T, Tysnes OB, Auburger G, Gispert S, Bonini NM, Andersen PM, Gitler AD.

Hum Mol Genet. 2011 May 1;20(9):1697-700. doi: 10.1093/hmg/ddr045. Epub 2011 Feb 3.

Supplemental Content

Support Center